A phase IV open label randomised controlled trial of rituximab in induction therapy for living donor renal transplantation.

Trial Profile

A phase IV open label randomised controlled trial of rituximab in induction therapy for living donor renal transplantation.

Suspended
Phase of Trial: Phase IV

Latest Information Update: 28 Jan 2016

At a glance

  • Drugs Rituximab (Primary) ; Hydrocortisone; Mycophenolate mofetil; Prednisolone; Tacrolimus
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Acronyms ReMIND; RituxiRT
  • Most Recent Events

    • 28 Jan 2016 According to the United Kingdom Clinical Research Network record, status changed from recruiting to suspended.
    • 18 Nov 2015 Accrual to date is 24% according to United Kingdom Clinical Research Network.
    • 07 Oct 2015 Accrual to date is 23% according to United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top